Joint Formulary & PAD

Committees : ASPH DTC

Profiles (0)

No records returned.

Committee Recommendations (4)

05 Feb 25

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

04 Sep 24

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

27 Nov 14
The DTC approved the updated guidelines for medicines in the peri-operative period.
28 Nov 13

The committee supported the use of nepafenac within its licensed indications. As treatment is short term postoperatively (up to 60 days with a review by the specialist 1 month post operatively) it was agreed that this would be considered as a red drug on the traffic light system.